As an AliExpress affiliate, we may earn a commission from qualifying purchases.
Alopecia areata (AA) is autoimmune: the immune system attacks hair follicles, causing round bald patches or, in severe cases, total scalp (alopecia totalis) or whole-body (universalis) loss. It is not androgenetic pattern loss, so minoxidil and finasteride are not the answer. The breakthrough is a class of oral drugs — JAK inhibitors — that calm the immune attack: baricitinib (Olumiant, FDA-approved for AA in 2022), ritlecitinib (Litfulo, 2023, from age 12), and deuruxolitinib (Leqselvi, approved 2024 and launched in 2025). In severe AA, a meaningful share of patients regrow substantial hair over 6-12 months, but the benefit can fade if the drug stops, and these are immune-modulating medicines with boxed warnings (serious infections, blood clots, some cancers) that need a dermatologist's screening and monitoring. They are also costly and not always covered. If you have sudden round patches, short broken 'exclamation-mark' hairs, or rapid widespread loss, see a dermatologist — AA is treatable, and the JAK era has genuinely changed the outlook.
Research & evidence
How treatment evolved
2022FDA approves baricitinib (Olumiant) on June 13, 2022 for adults with severe alopecia areata — the first systemic/oral treatment ever approved in the US for the disease.
2022Pivotal BRAVE-AA1 and BRAVE-AA2 phase 3 results published in the New England Journal of Medicine (King et al., NEJM 2022;386:1687–1699), establishing oral JAK1/2 inhibition as effective for severe AA.
2023FDA approves ritlecitinib (Litfulo), a JAK3/TEC inhibitor, on June 23, 2023 for severe AA in adults and adolescents aged 12+ — the first treatment approved for the adolescent population.
2024FDA approves deuruxolitinib (Leqselvi), an oral JAK1/2 inhibitor, on July 25, 2024 for adults with severe AA — the third JAK inhibitor approved for the indication.
Key clinical studies
King et al. (BRAVE-AA1 & BRAVE-AA2), 20222022
Two randomized, double-blind, placebo-controlled phase 3 trials; 654 (BRAVE-AA1) + 546 (BRAVE-AA2) adults with severe AA (baseline SALT >=50)
At week 36, a SALT score <=20 (>=80% scalp coverage) was achieved by 38.8% on baricitinib 4 mg, 22.8% on 2 mg, vs 6.2% on placebo (BRAVE-AA1); and 35.9%, 19.4%, vs 3.3% respectively (BRAVE-AA2).
NEJM (N Engl J Med 2022;386:1687-1699)
King et al. (ALLEGRO phase 2b/3), 20232023
Randomized, double-blind, placebo-controlled phase 2b-3 trial; 718 patients aged >=12 with AA and >=50% scalp hair loss, 118 sites in 18 countries
At week 24, 23% on ritlecitinib 50 mg/day achieved SALT<=20 vs 2% placebo (p<0.0001); rose to ~43% by week 48
Randomized, double-blind, placebo-controlled phase 3 trial; adults 18-65 with AA and >=50% scalp hair loss (part of the ~1,220-patient THRIVE-AA1/AA2 program)
At week 24, a SALT score <=20 was achieved by 41.5% on deuruxolitinib 12 mg twice daily and 29.6% on 8 mg twice daily vs ~0.8% on placebo.
JAAD (J Am Acad Dermatol 2024)
Latest research: Recent research (2023-2026) emphasizes long-term durability and safety data — e.g., 104-week BRAVE-AA and 2-3 year ALLEGRO-LT follow-ups showing sustained or improving regrowth — alongside the expansion of oral JAK inhibitors to adolescents (ritlecitinib) and comparative/real-world effectiveness and head-to-head positioning among baricitinib, ritlecitinib, and deuruxolitinib. Note: deuruxolitinib's US launch was delayed by patent litigation despite its 2024 approval.
Summaries reflect published, peer-reviewed research and are not medical advice. See the linked sources for details.
Is alopecia areata the same as male or female pattern baldness?
No. Alopecia areata is autoimmune and usually causes round patches or sudden loss; pattern baldness is hormonal and gradual. They need different treatments, so a dermatologist should tell them apart.
Can I get JAK inhibitors without a doctor?
No. JAK inhibitors are prescription immune-modulating drugs with boxed warnings, so they require dermatologist screening, monitoring and supervision — they are not over-the-counter.
Not medical advice. General education only; it does not replace diagnosis or treatment by a licensed professional. Consult a board-certified dermatologist before starting, stopping or changing any treatment.